An updated methodology to review developing-country vaccine manufacturer viability
Authors:
- Nicholas LuterNLNicholas Luter
- Ritu KumarRKRitu Kumar
Open Access
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Twenty-five years of the WHO vaccines prequalification programme (1987–2012): Lessons learned and future perspectivesVaccine, 2015
- Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countriesVaccine, 2012
- Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, BrazilVaccine, 2012
- Economical Value of Vaccines for the Developing Countries—The Case of Instituto Butantan, a Public Institution in BrazilPLOS Neglected Tropical Diseases, 2011
- During The ‘Decade Of Vaccines,’ The Lives Of 6.4 Million Children Valued At $231 Billion Could Be SavedHealth Affairs, 2011
- Access to vaccine technologies in developing countries: Brazil and IndiaVaccine, 2007
- The Meningitis Vaccine ProjectVaccine, 2007
- Lock in, the state and vaccine development: Lessons from the history of the polio vaccinesResearch Policy, 2005
- Vaccine quality—can a single standard be defined?Vaccine, 2001
- Global DTP manufacturing capacity and capability. Status report: January 1995Vaccine, 1996